LYT-100 (Deupirfenidone)

About PureTech Health

PureHealth Health is a biotherapeutics company with a proven track record of translating scientific innovation into clinical and commercial value. It employs a distinctive operational model, acting as a biotech 'studio' that conceives, founds, and advances new companies around specific scientific programs. This approach has generated 29 therapeutic candidates, including three that have progressed from inception at PureTech to FDA approval. The company's strategy focuses on unlocking the potential of validated biology by improving efficacy, enabling oral delivery, or enhancing tolerability.

About LianBio

LianBio operates as a strategic bridge, connecting innovative global biopharmaceutical assets with high-growth Asian markets, particularly China. The company leverages its deep regional expertise in development, regulatory affairs, and commercialization to advance a portfolio of clinical-stage and commercial-stage therapies. Its business model mitigates early-stage R&D risk by focusing on de-risked, externally sourced candidates with proof-of-concept data. A key strategic move was the announcement in late 2023 to wind down operations and return capital to shareholders, following a review of its strategic alternatives.

Therapeutic Areas

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs